Aditxt (ADTX) Cash from Investing Activities (2020 - 2026)
Aditxt (ADTX) recorded quarterly Cash from Investing Activities of -$10379.0 in Q1 2026, up 24.48% quarter-over-quarter from -$13743.0 in Q4 2025.
Aditxt (ADTX) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Aditxt's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$10379.0 for Q1 2026.
- In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$10379.0; the TTM figure through Mar 2026 stood at -$2.8 million (changed N/A YoY), while the FY2025 annual figure was -$2.4 million, up 51.23% from the prior year.
- Cash from Investing Activities was -$10379.0 for Q1 2026 at Aditxt, up from -$13743.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $179726.0 in Q4 2022 to a low of -$2.7 million in Q4 2024.
- Historically, Cash from Investing Activities has averaged -$389131.5 across 5 years, with a median of -$10379.0 in 2026.
- The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities jumped 102.12% in 2022, then sank 13367.29% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $179726.0 in 2022, then plunged by 105.21% to -$9356.0 in 2023, then plunged by 29186.02% to -$2.7 million in 2024, then soared by 99.5% to -$13743.0 in 2025, then rose by 24.48% to -$10379.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$10379.0 (Q1 2026), -$13743.0 (Q4 2025), and -$2.7 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | -10,379.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,379.00 |
| Mar 31, 2026 | -10,379.00 |
| Dec 31, 2025 | -13,743.00 |
| Dec 31, 2025 | -13,743.00 |
| Dec 31, 2024 | -2.74 Mn |
| Dec 31, 2024 | -2.74 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Sep 30, 2024 | -1.26 Mn |
| Sep 30, 2023 | -9,356.00 |
| Sep 30, 2023 | -9,356.00 |
| Jun 30, 2023 | -2.00 |
| Jun 30, 2023 | -2.00 |
| Mar 31, 2023 | -5,049.00 |
| Mar 31, 2023 | -5,049.00 |
| Dec 31, 2022 | 179,726.00 |
| Dec 31, 2022 | 179,726.00 |
| Sep 30, 2022 | 87,438.00 |
| Sep 30, 2022 | 87,438.00 |
| Jun 30, 2022 | -135,715.00 |
| Jun 30, 2022 | -135,715.00 |